When it comes to treating the opioid crisis, digital tools may be able to tackle some of the trickiest issues that the current care model cannot, according to a recently released Rock Health report. The report zeros in on some of the major road blocks in treating addiction and how digital could be the key to addressing these needs.
Those challenges include the variability between treatment...
Hayward, California-based Chrono Therapeutics, which is developing a sensor-enabled nicotine patch with a connected app, has raised $47.6 million in Series B financing. The round was led by Kaiser Permanente Ventures and will go towards further development of the company’s digital drug therapy platform.
Chrono Therapeutics’ flagship product, which won’t be ready for consumers until as late as...
Chrono Therapeutics, the maker of a wearable, smartphone-connected drug delivery device for smoking cessation, has completed a small randomized trial that shows that nicotine replacement therapy delivered with its device can reduce cravings to a statistically significant degree compared to a placebo delivered the same way.
The trial was a randomized, double-blinded study of 24 adult men who...
The National Cancer Institute (NCI) has awarded Chrono Therapeutics a Small Business Innovation Research (SBIR) grant of up to $2.3 million for product development of the digital portion of the company's smoking cessation therapy offering. The new grant will fund Chrono's final clinical trial for its product.
This is the second grant Chrono has received from the NCI. The first, $2.23 million...
Chrono Therapeutics, a Hayward, California-based company working on a new wearable for smoking cessation and drug delivery, has received an investment from seed fund Rock Health. According to MedCity News, Rock Health has contributed $100,000. This brings the company's total funding to about $32.1 million.
Chrono disclosed its most recent round in June 2014. It included contributions from Canaan...
Chrono Therapeutics, a Hayward, California-based company working on a new wearable for smoking cessation and drug delivery, has raised $32 million in its first round of funding. The round was led by Canaan Partners and 5 am Ventures. Additional contributors included Fountain Healthcare Partners, and two strategic investors: GE Ventures and the Mayo Clinic.
The company's flagship product SmartStop...
